MedTech News
AI distinguishes glioblastoma from look-alike cancers during surgery
A Harvard Medical School–led research team has developed an AI tool that can reliably tell apart two look-alike cancers found in the brain but with different origins, behaviors, and treatments.
Zimmer Biomet Announces Japan PMDA Approval of Iodine-Treated Total Hip Replacement System
iTaperloc Complete and iG7 Hip System with Iodine Technology inhibits bacterial adhesion and prevents biofilm formation on the implant surface to help address the issue of Periprosthetic Joint Infection after total joint replacement
Fiber-optic method allows real-time monitoring of Alzheimer’s plaques in freely behaving mice
Alzheimer’s disease is marked by the buildup of amyloid plaques in the brain, but most ways of studying these deposits in mouse models require sacrificing the animals. That limits researchers’ ability to follow how the disease develops or how treatments work over time.
Smart blood: How AI reads your body’s aging signals
Could a simple blood test reveal how well someone is aging?
EssilorLuxottica wins FDA OK for myopia-slowing eyeglass lenses
Investigators saw a 71% reduction in myopia progression in children who used the lenses for two years.
AngioSafe emerges from stealth with FDA clearance for Santreva-ATK catheter
AngioSafe announced it has received FDA 510(k) clearance and CE marking for its Santreva-ATK endovascular revascularization catheter.
Accuray Launches All-in-One Radiotherapy Solution With Advanced Capabilities Designed to Set a New Standard in Cancer Care
MADISON, Wis., Sept. 26, 2025 /PRNewswire/ — Accuray Incorporated (NASDAQ: ARAY) announced today that the company is advancing its legacy of leadership in adaptive radiotherapy with the introduction of the Accuray Stellar™* Solution. Initially for the U.S. market, the new Accuray technology is not just a system, it’s a solution, comprised of a comprehensive tool set designed to empower clinical teams to address the evolving treatment needs of patients undergoing radiotherapy.
Nexalin Technology Announces Issuance of U.S. Patent Covering HALO Clarity Device Featuring DIFS Technology
The newly issued patent strengthens Nexalin’s expanding intellectual property estate, supporting the Company’s DIFS platform and ongoing clinical and regulatory initiatives